内容概要：化妆品原料是构成化妆品的基础，涵盖多种来源，决定产品功效与竞争力。近年来，随着消 费者对产品品质、成分安全与功效可靠性的要求日益提升，中国化妆品行业正从"高速增长"全面转 向"高质量发展"，2025年全渠道交易额达11042.45亿元。全球化妆品原料市场稳步增长，2024年规模已 达3592亿元，亚太地区尤其是中国市场成为增长核心。中国化妆品原料市场规模快速增长，2024年约为 650.04亿元，预计2026年达716.67亿元。其中，活性原料、植物提取原料和生物发酵原料市场规模均持 续扩大，生物发酵原料增速最快。企业竞争格局上，国际巨头主导高端市场，本土企业快速崛起，研发 创新成行业主旋律。未来，中国化妆品原料行业将以技术创新为核心，加速国产化替代，同时强化合规 绿色发展，向高质量、高创新、高合规方向稳步迈进。 上市企业：华熙生物（688363.SH）、贝泰妮（300957.SZ） 相关企业：山东福瑞达医药集团有限公司、浙江湃肽生物股份有限公司、北京东方淼森生物科技有限公 司、上海辉文生物技术股份有限公司、上海华伊美化妆品有限公司、山东安华生物医药股份有限公司、 吉林省健维天然生物科技有限公司、喜 ...

Core Viewpoint - Beijing Stock Exchange has issued a second round of inquiry regarding the IPO application of Shanghai Jiakai Biological Co., Ltd., focusing on customer cooperation stability, performance growth sustainability, gross margin authenticity, and compliance of equity changes [1] Group 1: Company Overview - Jiakai Biological specializes in the research, production, and sales of cosmetic functional raw materials, with a client base that includes major brands such as Proya, Fuda, and Huaxi [1] - The company reported revenues of 182.62 million yuan in 2022, 217.50 million yuan in 2023, and projected 242.44 million yuan in 2024, indicating a consistent growth trend [2][3] Group 2: Financial Performance - Revenue for the first half of 2025 is reported at 122.12 million yuan, with a year-on-year growth of 12.28% [2] - The company achieved a revenue of 194.81 million yuan for the first nine months of 2025, reflecting a 7.91% increase compared to the same period last year [3] Group 3: Market Position - Jiakai Biological holds a market share of approximately 1.64% in the domestic functional raw materials market, which is projected to reach 14.8 billion yuan in 2024 [5] - The company claims to have deeply integrated into the core ecosystem of China's cosmetic industry, establishing strong partnerships with leading domestic brands [5] Group 4: Customer Dynamics - The company has experienced revenue declines from major clients in both self-produced and OEM products, with core customers contributing to 63.85% of revenue in the first half of 2025 [4] - The inquiry requires Jiakai Biological to explain the reasons behind the revenue fluctuations from key clients and the stability of customer relationships [4] Group 5: Gross Margin Analysis - Jiakai Biological's gross margin has remained stable at over 63% from 2022 to mid-2025, which raises questions about its sustainability compared to industry peers [6] - The inquiry demands an analysis of the factors affecting gross margin stability, including product structure and pricing mechanisms [6] Group 6: Future Projects - The company plans to raise 309.56 million yuan for a project to produce 50 tons of functional plant extracts annually, with a focus on high-purity single-component products [6][7] - The inquiry seeks clarification on the advantages of the new products compared to existing ones and the potential market demand [7] Group 7: Shareholding Structure - The company has three main actual controllers who collectively hold significant voting rights, with an agreement in place to maintain consistent decision-making for 36 months post-IPO [8] - The inquiry requires details on the decision-making mechanisms and dispute resolution processes among the actual controllers [8]

Core Insights - The article presents a summary of stock performance based on three testing strategies, highlighting a total of 15 stocks with an average dividend yield of 4.60% and an average price-to-earnings (P/E) ratio of 32.54 [1] Group 1: Stock Performance Summary - The intersection of the three strategies includes 15 stocks with an average dividend yield of 4.60% and an average P/E ratio of 32.54 [1] - The union of the three strategies results in 20 stocks with an average dividend yield of 4.76% and an average P/E ratio of 33.96, indicating a higher dividend yield compared to the previous period while the P/E ratio is lower [2][3] Group 2: High-Value Stocks - Jizhong Energy (000937) is a leading coal mining company with a P/E ratio of 48.51 and a high dividend yield of 10.89%, despite a significant drop in net profit [4] - Thinking Control (603508) specializes in railway safety equipment with a P/E ratio of 18.2 and a dividend yield of approximately 5.8%, showing a positive net profit growth [4] - Hangmin Co. (600987) is a leader in the dyeing industry with a low P/E ratio of 10.06 and a stable dividend yield of 3.23%, despite facing industry challenges [5] - Kemin Food (002661) is a leading noodle manufacturer with a P/E ratio of 15.2 and a dividend yield of about 4.8%, although it has experienced a decline in net profit [5] Group 3: Mid-Value Stocks - Zhongjian Vehicles (301039) is a global leader in commercial vehicles with a P/E ratio of 20.97 and a stable net profit despite a year-on-year decline [6] - Yabao Pharmaceutical (600351) is a leader in traditional Chinese medicine with a P/E ratio of 22.3 and a dividend yield of approximately 3.5%, showing stable cash flow [6] - Qianjiang Motorcycle (000913) is a major player in the motorcycle industry with a P/E ratio of 18.5 and a dividend yield of about 2.1%, facing market challenges [6] - Wufangzhai (603237) is a well-known brand in the rice dumpling market with a P/E ratio of 25.6 and a dividend yield of approximately 3.8%, despite a decline in net profit [6] Group 4: Cautious Stocks - Hengsheng Energy (605580) operates in the thermal power sector with a high P/E ratio of 61.83, indicating overvaluation concerns [7] - S Jiatong (600182) is in the tire industry with a P/E ratio of around 45 and a low dividend yield of 0.3%, facing profitability challenges [7] - Delmar (301332) is a small appliance company with a P/E ratio of about 40, showing weak brand strength compared to peers [7] - Wenfeng Co. (601010) is a retail company with a P/E ratio of about 22, experiencing a significant decline in net profit [7]

Group 1 - The core point of the news is that Shanghai Jiakai Biological Co., Ltd. has responded to the first round of inquiry from the Beijing Stock Exchange regarding compliance issues related to equity changes, control stability, product quality risks, and the sustainability of performance growth [2][4] Group 2 - Jiakai Biological was established in 2015 and focuses on the research, production, and sales of cosmetic functional raw materials, primarily used in skincare, masks, and hair care products [4] - The company plans to raise 310 million yuan through its IPO, which will be fully allocated to a project for annual production of 50 tons of functional plant extracts [4] - The company has seen significant valuation growth, from 3 billion yuan in 2020 to 24.7 billion yuan in 2025, reflecting an increase of over 7 times in five years [5] Group 3 - Revenue figures for Jiakai Biological from 2023 to the first three quarters of 2025 are 218 million yuan, 242 million yuan, and 195 million yuan, with year-on-year changes of 19.1%, 11.46%, and 7.91% respectively [5] - Net profit for the same period is 48 million yuan, 57 million yuan, and 47 million yuan, with year-on-year changes of -12.82%, 19.83%, and 16.91% respectively [5]

Core Viewpoint - Shanghai Jiakai Biological Co., Ltd. (referred to as "Jiakai Biological" or "the issuer") has responded to the first round of inquiries from the Beijing Stock Exchange regarding its IPO, addressing issues related to compliance of equity changes, stability of control, business model and product technology advancement, compliance of cosmetic raw material qualifications, product quality risks, sustainability of performance growth, capacity digestion ability, and high supplier concentration and fair pricing of procurement [1] Equity Changes and Control - The exchange focused on the compliance of the company's past equity changes, noting significant price differences in equity transfers in August 2022 and January 2024, questioning the rationale behind these differences and potential conflicts of interest [2] - Jiakai Biological explained that the price differences were due to internal adjustments by the same fund manager and variations in cooperation terms, asserting that the pricing was negotiated based on performance and development expectations, thus justifying the differences without any conflict of interest [2] - The company emphasized the stability of control, stating that the three joint actual controllers maintain a stable control structure through a concerted action agreement and three holding platforms, with no significant disagreements during the reporting period [2] Performance and Capacity - Financial data indicates steady growth in the company's performance, with revenue increasing from 183 million yuan to 242 million yuan and net profit rising from 55 million yuan to 57 million yuan from 2022 to 2024 [3] - Capacity utilization rates for green natural functional raw materials were 151.15%, 61.19%, and 49.87%, while for bio-synthetic functional raw materials, the rates were 93.09%, 19.32%, and 25.33% during the same period [3] - The company reported that sales to its top five customers accounted for 36.61%, 32.30%, and 32.88% of total sales during the reporting period, indicating some volatility in sales amounts [3] Supplier Concentration and Procurement - Jiakai Biological's procurement from its top five suppliers accounted for 64.56%, 62.65%, and 61.57% of total procurement during the reporting period, indicating a higher concentration than industry peers [6] - The largest supplier, Lanzhou Xinweirong Chemical Technology Co., Ltd., had procurement shares of 26.45%, 24.26%, and 29.04% [6] - The company explained that the high supplier concentration is due to industry characteristics, and procurement pricing is determined through market negotiations, with a supplier evaluation and alternative mechanism in place to mitigate risks associated with reliance on single suppliers [6]

Group 1 - The company has strict internal control management for the quality standards and storage period of its sunscreen products, ensuring they are in optimal condition before production [2] - The shelf life of the company's sunscreen products ranges from 2 to 5 years [2]

Group 1: Construction Materials Industry - The central economic work conference emphasizes "internal strength" and highlights the contradiction of "strong supply and weak demand" in the construction materials industry, indicating a shift towards supply-side reforms and potential investment opportunities in the cement sector [2][6][9] - The policy focus has shifted from "extraordinary counter-cyclical adjustments" to "increasing counter-cyclical and cross-cyclical adjustment efforts," suggesting a more gradual adjustment in demand-side policies for the upcoming year [2][6] - The cement sector remains the most valuable investment area within the construction materials industry, with expectations for a new round of supply-side reform [2][6] Group 2: Cosmetics Raw Materials Industry - The Chinese cosmetics raw materials market is projected to grow from CNY 1147.80 billion in 2019 to CNY 1603.90 billion by 2024, with a compound annual growth rate (CAGR) of 6.9% [10] - The peptide raw materials market is expected to grow from CNY 11.2 billion in 2019 to CNY 21.7 billion by 2024, with a CAGR of 14.1% [10] - Leading companies in the industry include Weiqi Technology and Jiakai Biological, with Weiqi holding a 6.6% market share in the peptide raw materials sector [10][11] Group 3: Transportation Industry - The logistics demand in emerging markets is showing robust growth, with Jitu Express achieving record daily collection volumes in Brazil [15][16] - The international air transport association (IATA) forecasts a stable profit outlook for airlines, with a projected total net profit of USD 41 billion in 2026 [18] - The supply chain bottlenecks continue to restrict the growth of the aviation industry, with a structural mismatch between demand and available aircraft [18] Group 4: Agriculture, Forestry, Animal Husbandry, and Fishery Industry - The pig price is expected to remain weak, with a recent increase to CNY 11.54/kg, but overall industry losses persist [31][32] - The central economic work conference has introduced policies aimed at stabilizing pig prices and enhancing farmers' income, indicating a shift towards protecting farmers' rights and promoting innovation [32] - The chicken industry faces a "high capacity, weak consumption" dilemma, with leading companies likely to gain market share as they adapt to changing conditions [33]

Core Viewpoint - The successful implementation of the first green foreign debt pilot business by Bank of Communications in Zhejiang Province marks a significant step in translating green foreign debt policies into practice, providing local enterprises with new financing channels and reducing cross-border financing costs [1][2]. Group 1: Policy Implementation - The green foreign debt pilot policy in Zhejiang Province was officially introduced in December this year, leading to the rapid establishment of a joint service team by Bank of Communications to support enterprises [1]. - The team includes marketing and professional support, with proactive engagement from customer managers to meet enterprise needs and in-depth research on policy details by the international business team [1]. Group 2: Company Profile - The borrowing enterprise, Zhejiang Kaisi Technology Development Co., Ltd., established in 2008, focuses on the research, production, and sales of cosmetic raw materials and is recognized as a national high-tech enterprise [1]. - The company is also classified as a green specialized enterprise and is committed to low-carbon transformation through technology upgrades and energy efficiency improvements [1]. Group 3: Project Details - The green foreign debt of $1.5 million will be specifically used for energy-saving upgrades and process optimization of production equipment, further reducing carbon emissions [2]. - The successful registration of this green foreign debt is a key outcome of collaboration among banks, enterprises, and government, creating a replicable and scalable service model [2].

Investment Rating - The report indicates a positive outlook for the cosmetics raw materials industry, highlighting the stable growth of the downstream cosmetics sector and the leading positions of companies like Weiqi Technology and Jiakai Biological [1]. Core Insights - The cosmetics raw materials industry in China is projected to grow from CNY 1,147.80 billion in 2019 to CNY 1,603.90 billion by 2024, with a compound annual growth rate (CAGR) of 6.9% [2][12]. - The peptide active ingredients market is expected to grow from CNY 11.2 billion in 2019 to CNY 21.7 billion by 2024, achieving a CAGR of 14.1% [2][16]. - The plant extract raw materials market is anticipated to increase from CNY 204.5 billion in 2019 to CNY 270.2 billion by 2024, with a CAGR of 6.5% [2][20]. - Weiqi Technology holds a 6.6% market share in the peptide raw materials sector, ranking first in China [2][25]. - Jiakai Biological has established a leading position in the plant extract efficacy raw materials field, with significant revenue growth [2][33]. Summary by Sections 1. Growth of the Cosmetics Raw Materials Industry - The cosmetics raw materials market in China is expected to reach CNY 1,604 billion by 2024, driven by the stable growth of the cosmetics industry [2][5]. - The global cosmetics market is projected to reach USD 550.3 billion in 2024, with China being the largest market [5][8]. 2. Performance of Weiqi Technology and Jiakai Biological - Weiqi Technology's revenue for the first half of 2025 is CNY 132 million, a year-on-year increase of 34.6%, with a net profit of CNY 40.2 million, up 68.76% [2][30]. - Jiakai Biological's revenue for the first three quarters of 2025 is CNY 195 million, reflecting a year-on-year growth of 7.91%, with a net profit of CNY 47.3 million, up 16.91% [2][37]. 3. Market Trends and Valuation - The median price-to-earnings (P/E) ratio for the North Exchange consumer service sector increased to 50.1X, indicating a slight upward trend [2][50]. - The total market capitalization of consumer service companies on the North Exchange rose from CNY 1,096.29 billion to CNY 1,152.85 billion [2][43]. 4. Competitive Landscape - The cosmetics raw materials industry is characterized by a low concentration, with many small-scale companies primarily serving domestic mid-to-low-end markets [2][12]. - The demand for active ingredients, particularly peptides, is growing rapidly, driven by consumer preferences for effective skincare products [2][15].

Group 1 - The core announcement is about the successful registration of the cosmetic ingredient Pentapeptide-18 by Chengdu Saintno Biological Technology Co., Ltd. through the National Medical Products Administration [1] - Pentapeptide-18 is a skin protectant that can be used in various cosmetic products, with a safe usage level of up to 1.86% in finished products [1] - The registration enhances the company's product matrix and broadens the application scenarios for beauty peptide products, positively impacting the company's operational development [2] Group 2 - The registration number for Pentapeptide-18 is Guozhuangyuanbeizi 20250152, and it is registered under Chengdu Kaijie Peptide Technology Co., Ltd. [1] - The ingredient is designed to assist in improving skin irritation conditions, thereby achieving skin protection [1]